Abstract 1913P
Background
Transbronchial microwave lung ablation has been a novel local therapy for early lung cancers and lung oligometastases, especially in patients who have high surgical risks or suffer from multifocal lung tumours. This is a single institute retrospective review of the 5-year result of transbronchial microwave ablation using electromagnetic navigation bronchoscopy guidance in the hybrid operating room.
Methods
Between March 2019 and March 2024, 223 nodules in 145 patients were treated. Eligible lung nodules were either proven lung cancers, metastases, or radiologically suspicious. Safety and mid-term control rate of the technique were assessed.
Results
Mean maximal diameter of lung nodules was 11.8mm (range 6-29mm), and bronchus sign was positive in only 24.7% of them. Technical success rate was 100%, although 104 (46.6%) nodules required double ablation and 25 (11.2%) required triple or more ablation for adequate coverage. Mean minimal ablation margin was 6.3mm. Concomitant lung resection for other nodules was performed in 16 cases. Mean hospital stay was 1.56 days, 172 cases (77.1%) and 214 cases (95.9%) were discharged by post-ablation day 1 and 3 respectively. Complications included mild pain which did not require hospitalization (6.7%), pneumothorax requiring drainage (3.6%), hemoptysis (2.7%), post-ablation reaction (2.2%) and pleural effusion (1.8%). Mean follow up for all cases is 25.3 months. Thirteen cases of local ablation site recurrence (5.8%) have been identified, which were treated by re-ablation, stereotactic radiation therapy or surgery.
Conclusions
Transbronchial microwave ablation is a safe and novel ablative technique, and has encouraging mid-term local control rate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Research Grants Council (RGC) University Grant Committee Hong Kong, no: 14119019.
Disclosure
R. Lau: Financial Interests, Personal, Advisory Board: Medtronic. C. Ng: Financial Interests, Institutional, Speaker, Consultant, Advisor: Johnson and Johnson, Medtronic, USA, Siemens Healthineer. All other authors have declared no conflicts of interest.
Resources from the same session
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18